MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 11 - per page Next page
Order by
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
Gene targeting and localized delivery of anti-neoplastic agents More
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
Novel small molecule inhibitors of c-Met signaling; these small molecules selectively bind to c-Met and have an IC50 in the micromolar range. More
Experiments in vitro demonstrate that these novel SMO inhibitors potentially suppress the growth of cancer cells and inhibit the expression of the HH/PTCH pathway genes. More
Compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines More
Screening tool for the detection of breast and other cancers More
Intravenously administered nanoparticles selectively cross the blood-brain barrier of brain tumors and accumulate within brain tumor cells but not normal brain cells More
This new technology distinguishes between cytostatic and cytotoxic compounds, thereby significantly reducing the time and cost required to screen anti-tumor agents. More
Displaying 1..10 of 11 - per page Next page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
ShareVault
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us